Understand the source comparison
Cagrilintide Stacking: Peptide Compatibility Comparison
GLP-1 Agonists Semaglutide, Liraglutide GLP-1 receptor Yes. Clinically validated Stagger injections by 3–4 days; sequential titration required Strongest evidence for synergistic weight loss with manageable side effects Dual Agonists (GLP-1/GIP) Tirzepatide, Ma
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 Agonists
- Semaglutide, Liraglutide
- GLP-1 receptor
- Yes. Clinically validated
- Stagger injections by 3–4 days; sequential titration required
- Strongest evidence for synergistic weight loss with manageable side effects
- Dual Agonists (GLP-1/GIP)
- Tirzepatide, Mazdutide
- GLP-1 + GIP receptors
- Yes. Mechanistically compatible
- Same as GLP-1 agonists; monitor cumulative GI effects
- Compatible but not clinically tested; expect additive nausea during titration
- Triple Agonists
- Retatrutide (GLP-1/GIP/Glucagon)
- GLP-1 + GIP + Glucagon
- No. Overlapping satiety pathways
- N/A. Receptor duplication
- Glucagon agonism overlaps with amylin effects; stacking adds side effects without proportional benefit
- Growth Hormone Secretagogues
- CJC1295 Ipamorelin, MK 677
- Ghrelin + GHRH receptors
- Yes. Distinct pathways
- Dose GH peptides at night, cagrilintide in AM
- No receptor conflict; circadian separation minimizes interaction
- Amylin Agonists
- Pramlintide (Symlin)
- Amylin receptor (AMY1/2/3)
- No. Same receptor target
- N/A. Direct duplication
- Stacking two amylin agonists is receptor duplication, not pathway complementation
- Metabolic Peptides
- Tesofensine, AOD-9604, MOTS-c
- Monoamine transporters, lipolysis, mitochondrial
- Yes. Independent mechanisms
- No specific timing constraint
- Compatible but monitor cumulative appetite suppression